Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients
BackgroundGlycogen storage disease type 1b (GSD1b) is an ultra-rare autosomal recessive disorder, caused by mutations in SLC37A4 gene. Affected patients present with episodes of fasting hypoglycemia and lactic acidosis, hepatomegaly, growth retardation, hyperlipidemia and renal impairment. In additi...
Main Authors: | Zufit Hexner-Erlichman, Maria Veiga-da-Cunha, Yoav Zehavi, Zahava Vadasz, Adi D. Sabag, Sameh Tatour, Ronen Spiegel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.1071464/full |
Similar Items
-
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
by: Arianna Maiorana, et al.
Published: (2023-04-01) -
The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience
by: Joanna Bidiuk, et al.
Published: (2022-06-01) -
Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study
by: Sarah C. Grünert, et al.
Published: (2023-05-01) -
A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation
by: Shiri Curelaru, et al.
Published: (2022-09-01) -
Primary autoimmune myelofibrosis: A case report in a child
by: Zufit Hexner‐Erlichman, et al.
Published: (2020-07-01)